

Unterach, the 2nd of September 2015

Clinical Trial Cancellation

Sponsor: EVER Neuro Pharma
Protocol Number: EVE-AT-0412
EudraCT Number: 2012-004944-31

To whom it may concern,

During the Advisory Board Meeting at the 30th of August 2015 it has been decided to cancel the EVE-AT-0412/DAT-study within its start-up phase and prior to any site-initiation.

Please find as accompanying document the official Advisory Board Statement.

Kindest regards,



EVER Neuro Pharma GmbH
4866 Unterach/Austria

02. SEP. 2015

Victoria Irzhevsky, PhD

Head of Clinical Research



EVER Neuro Pharma GmbH
4866 Unterach/Austria

02. SEP. 2015

Dr. Christian Langelüddecke

Project Manager Clinical Research

EVER Neuro Pharma GmbH

Oberburgau 3, 4866 Unterach, Austria
Tel.: +43 7065 20 555 – 0
Fax: +43 7065 20 555 – 910
e-mail: office@everpharma.com

Manufacturing site:
Mondiseestraße 11, 4866 Unterach, Austria

Commercial Register No.: FN 316993 t
Registration Court: District Court Salzburg

Bank details:

UniCredit Bank Austria AG
Kto. 52362 004 005, BLZ 12000 / IBAN AT35 1200 0529 6200 4005, BIC BKAUATWW (EUR)
Kto. 52362 004 002, BLZ 12000 / IBAN AT19 1200 0529 6200 4002, BIC BKAUATWW (USD)
Kto. 52362 004 004, BLZ 12000 / IBAN AT62 1200 0529 6200 4004, BIC BKAUATWW (RON)
Raiffeisenlandesbank Oberösterreich AG
Kto. 000-02.696.266, BLZ 34000 / IBAN AT96 3400 0000 0263 6266, BIC RZOOAT2L (EUR)
Kto. 701-02.696.263, BLZ 34000 / IBAN AT96 3400 0701 0263 6269, BIC RZOOAT2L (USD)
Raiffeisen Zentralbank Österreich AG
Kto. 1-04.164.091, BLZ 31000 / IBAN AT42 3100 0001 0416 4091, BIC RZBAAT33 (EUR)
Kto. 70-54.164.090, BLZ 31000 / IBAN AT23 3100 0070 5416 4090, BIC RZBAAT33 (USD)

Official Statement of the EVE-AT-0412/DAT Study Advisory Board

Barcelona, ESP

30th August 2015

To whom it may concern,

During the Advisory Board Meeting on August 30th 2015, it has been decided to cancel the EVE-AT-0412/DAT study within its start-up phase and prior to any site initiation.

The primary reason for this decision lies in the significant operational challenges. The projected substantial delay of the start of this trial cannot be justified in the dynamic environment of the current scientific framework.

Every effort will be made to share the lessons learned from this trial preparation and their implementation in the clinical development program for dementia at EVER Pharma with the larger academic community.

The Advisory Board would like to thank all study participants for their efforts and understanding.

Bank details:

UniCredit Bank Austria AG

Kto. 52962 004 005, BLZ 12000 / IBAN AT35 1200 0529 0200 4005, BIC BKAUATWW (EUR)

Kto. 52962 004 002, BLZ 12000 / IBAN AT19 1200 0529 6200 4002, BIC BKAUATWW (USD)

Kto. 52962 004 004, BLZ 12000 / IBAN AT02 1200 0529 0200 4004, BIC BKAUATWW (RON)

Raiffeisenlandesbank Oberösterreich AG

Kto. 000-02.696.268, BLZ 34000 / IBAN AT98 3400 0000 0269 6268, BIC RZOOAT2L (EUR)

Kto. 701-02.696.268, BLZ 34000 / IBAN AT96 3400 0701 0269 6268, BIC RZOOAT2L (USD)

Raiffeisen Zentralbank Österreich AG

Kto. 1-04.104.091, BLZ 31000 / IBAN AT42 3100 0001 0416 4091, BIC RZBAATWW (EUR)

Kto. 70-54.164.090, BLZ 31000 / IBAN AT23 3100 0070 5416 4090, BIC RZBAATWW (USD)